• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

EIDD-2801

Product ID E325125
Cas No. 2349386-89-4, 2492423-29-5
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $76.30 In stock
10 mg $136.30 In stock
25 mg $267.10 In stock
100 mg $790.30 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

EIDD-2801 (Molnupiravir) is an orally bioavailable broad spectrum antiviral compound that is effective against SARS-CoV2 infection.

Product Info

Cas No.

2349386-89-4, 2492423-29-5

Purity

≥98%

Formula

C13H19N3O7

Formula Wt.

329.3

Chemical Name

N-Hydroxy-5'-O-isobutyryl-3,4-dihydrocytidine

IUPAC Name

[(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate

Synonym

Molnupiravir; EIDD 2801; EIDD2801; MK-4482; β-D-N4-Hydroxycytidine-5′-isopropyl ester

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

E325125 MSDS PDF

Info Sheet

E325125 Info Sheet PDF

References

Sheahan TP, Sims AC, Zhou S. et al An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. scitranslmed.abb5883. Epub 2020 Apr 6. PMID: 32253226 PMCID: PMC7164393 DOI: 10.1126/scitranslmed.abb5883

Fischer W, Eron JJ, Holman W. et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. MedRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. Preprint. PMID: 34159342

Abdelnabi R, Foo CS, De Jonghe S. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. J Infect Disactions. 2021 Sep 1;224(5):749-753. doi: 10.1093/infdis/jiab361. PMID: 34244768 PMCID: PMC8408768 DOI: 10.1093/infdis/jiab361

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only